Abstract
Early clinical trials of glucose-insulin-potassium for acute myocardial infarction were inconclusive. However, several recent placebo-controlled, prospective, randomized clinical trials of glucose-insulin-potassium for acute myocardial infarction or metabolic support during and after cardiac surgery have demonstrated its efficacy. These clinical results are supported by experimental studies that have shown a strong protective effect of increased glycolytic substrate on ischemic myocardium in concert with an improved bioenergetic status.
MeSH terms
-
Adenosine Diphosphate / metabolism
-
Animals
-
Fatty Acids, Nonesterified / metabolism
-
Glucose / metabolism
-
Glucose / therapeutic use
-
Glycolysis / physiology*
-
Humans
-
Insulin / metabolism
-
Insulin / therapeutic use
-
Myocardial Infarction / metabolism
-
Myocardial Infarction / prevention & control*
-
Myocardial Reperfusion Injury / metabolism
-
Myocardial Reperfusion Injury / prevention & control*
-
Myocardium / metabolism*
-
Oxidative Phosphorylation
-
Oxygen Consumption
-
Potassium / metabolism
-
Potassium / therapeutic use
Substances
-
Fatty Acids, Nonesterified
-
Insulin
-
Adenosine Diphosphate
-
Glucose
-
Potassium